Biocon, Quark get DCGI nod for trials of new eye disease drug

Biopharmaceutical firm Biocon today said the Drug Controller General of India (DCGI) has given nod to it and partner Quark Pharmaceuticals to proceed with clinical trials on human subjects for a new drug candidate, 'QPI-1007' aimed for ocular neuroprotection. 

Biocon and Quark Pharmaceuticals also announced the randomisation of the first patient in India in the global Phase II/III study of the new drug candidate, the company said in a statement. 

Randomisation is the allo .. 

Read more at:
http://economictimes.indiatimes.com/articleshow/52881320.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Biocon cancer drug trial data positive from 3 clinical trials

MUMBAI: Indian biotech frontrunner Biocon and its global partner for biosimilars, Mylan, have announced positive data from phase 3 clinical trials of a proposed copy of trastuzumab, a complex injection used widely to treat a type of breast cancer. 

The trial results, being presented this week at the American Society of Clinical Oncology - a prestigious conference held annually in the US —gives the drugmakers an edge over rivals and will enable regulatory submissions for commercial la .. 

Read more at:
http://economictimes.indiatimes.com/articleshow/52612668.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst